Novel hierarchical CuS/ZnS hetero-nanowires were designed and successfully synthesized through a template-free and surfactant-free chemical solution method with a mixed solvent of dimethyl sulfoxide and ethylene glycol. The precursors of CuS and the molar ratio of Cu:Zn, play a crucial role in controlling the morphology of the CuS/ZnS heterostructure. The precursors of CuS serve both as a source material for chemical transformation to CuS and as sacrificial templates for the growth of ZnS nanosheets by adding zinc(ii) ions, finally forming a ZnS/CuS hierarchical nanomaterial with p-n heterojunctions. The as-prepared samples were examined by X-ray diffraction, X-ray photoelectron spectroscopy, scanning electron microscopy, transmission electron microscopy, UV-visible diffuse reflectance spectroscopy and Brunauer-Emmett-Teller measurements. Photocatalytic activities for methylene blue and rhodamine B were investigated under visible-light irradiation, and appreciably increased photocatalytic activity compared to individual counterparts is achieved by the hierarchical CuS/ZnS hetero-nanowires. The p-n heterojunction, one-dimensional nanostructures and large specific surface area are responsible for the improved photocatalytic activities.

Copper sulfide nanowires/reduced graphene oxide (CuSNWs/rGO) nanocompsites are successfully synthesized via a facile one-pot and template-free solution method in a dimethyl sulfoxide (DMSO)-ethyl glycol (EG) mixed solvent. It is noteworthy that the precursor plays a crucial role in the formation of the nanocomposites structure. SEM, TEM, XRD, IR and Raman spectroscopy are used to investigate the morphological and structural evolution of CuSNWs/rGO nanocomposites. The as-fabricated CuSNWs/rGO nanocompsites show remarkably improved Li-storage performance, excellent cycling stability as well as high-rate capability compared with pristine CuS nanowires. It obtains a reversible capacity of 620 mAh g(-1) at 0.5C (1C = 560 mA g(-1)) after 100 cycles and 320 mAh g(-1) at a high current rate of 4C even after 430 cycles. The excellent lithium storage performance is ascribed to the synergistic effect between CuS nanowires and rGO nanosheets. The as-formed CuSNWs/rGO nanocomposites can effectively accommodate large volume changes, supply a 2D conducting network and trap the polysulfides generated during the conversion reaction of CuS.

Novel copper sulfide (CuS) nanowire bundles with a diameter of about 6 nm and a length up to several micrometers are successfully synthesized by a template- and surfactant-free method in a dimethyl sulfoxide (DMSO)-ethyl glycol (EG) mixed solvent. The resulting CuS nanowire bundles are used as a cathode material in lithium-ion batteries and exhibit a large capacity and excellent cycling stability and rate capability. The unique structure of the CuS nanowire bundles is responsible for their excellent electrochemical performance. © 2014 Elsevier B.V. All rights reserved.

Multifunctional nanoparticles with combined diagnostic and therapeutic functions show great promise towards personalized nanomedicine. However, attaining consistently high performance of these functions in vivo in one single nanoconstruct remains extremely challenging. Here we demonstrate the use of one single polymer to develop a smart 'all-in-one' nanoporphyrin platform that conveniently integrates a broad range of clinically relevant functions. Nanoporphyrins can be used as amplifiable multimodality nanoprobes for near-infrared fluorescence imaging (NIRFI), magnetic resonance imaging (MRI), positron emission tomography (PET) and dual modal PET-MRI. Nanoporphyrins greatly increase the imaging sensitivity for tumour detection through background suppression in blood, as well as preferential accumulation and signal amplification in tumours. Nanoporphyrins also function as multiphase nanotransducers that can efficiently convert light to heat inside tumours for photothermal therapy (PTT), and light to singlet oxygen for photodynamic therapy (PDT). Furthermore, nanoporphyrins act as programmable releasing nanocarriers for targeted delivery of drugs or therapeutic radio-metals into tumours.

Nanoparticle-based theranostic agents have emerged as a new paradigm in nanomedicine field for integration of multimodal imaging and therapeutic functions within a single platform. However, the clinical translation of these agents is severely limited by the complexity of fabrication, long-term toxicity of the materials, and unfavorable biodistributions. Here we report an extremely simple and robust approach to develop highly versatile and biocompatible theranostic poly(vinyl alcohol)-porphyrin nanoparticles (PPNs). Through a "one-pot" fabrication process, including the chelation of metal ions and encapsulation of hydrophobic drugs, monodispersenanoparticle could be formed by self-assembly of a very simple and biocompatible building block (poly(vinyl alcohol)-porphyrin conjugate). Using this approach, we could conveniently produce multifunctional PPNs that integrate optical imaging, positron emission tomography (PET), photodynamic therapy (PDT), photothermal therapy (PTT) and drug delivery functions in one formulation. PPNs exhibited unique architecture-dependent fluorescence self-quenching, as well as photodynamic- and photothermal- properties. Near-infrared fluorescence could be amplified upon PPN dissociation, providing feasibility of low-background fluorescence imaging. Doxorubicin (DOX)-loaded PPNs achieved 53 times longer half-life in blood circulation than free DOX. Upon irradiation by near infrared light at a single excitation wavelength, PPNs could be activated to release reactive oxygen species, heat and drugs simultaneously at the tumor sites in mice bearing tumor xenograft, resulting in complete eradication of tumors. Due to their organic compositions, PPNs showed no obvious cytotoxicity in mice via intravenous administration during therapeutic studies. This highly versatile and multifunctional PPN theranostic nanoplatform showed great potential for the integration of multimodal imaging and therapeutic functions towards personalized nanomedicine against cancers.

Etk is a non-receptor tyrosine kinase, which provides a strong survival signal in human prostate cancer cells. Src, another tyrosine kinase that cross-activates with Etk, has been shown to play an important role in prostate cancer metastasis. Herein, we discovered a new class of Etk inhibitors. Within those inhibitors, CTA095 was identified as a potent Etk and Src dual inhibitor. CTA095 was found to induce autophagy as well as apoptosis in human prostate cancer cells. In addition, CTA095 inhibited HUVEC cell tube formation and "wound healing" of human prostate cancer cells, implying its role in inhibition of angiogenesis and metastasis of human prostate cancer. More interestingly, CTA095 could overcome Src inhibitor resistance in prostate cancer cells. It induces apoptosis in Src inhibitor resistant prostate cancer cells, likely through a mechanism of down regulation of Myc and BCL2. This finding indicates that simultaneously targeting Etk and Src could be a promising approach to overcome drug resistance in prostate cancer.